FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

Phase 2 Completed 64 enrolled M.D. Anderson Cancer Center Genentech, Inc. · collab

NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if the combination of fludarabine, cyclophosphamide, rituximab, and bevacizumab is effective in treating chronic lymphocytic leukemia in patients who have already been treated with chemotherapy. The safety of this treatment will also be studied.

Timeline

Start: 2007-02
Primary completion: 2014-10
Completion: 2014-10

Publications

Results Jain P, Lee HJ, Qiao W, Wierda W, Benjamini O, Burger J, Ferrajoli A, Estrov Z, Kantarjian H, Keating M, O'Brien S. FCR and bevacizumab treatment in patients with relapsed chronic lymphocytic leukemia. Cancer. 2014 Nov 15;120(22):3494-501. doi: 10.1002/cncr.28910. Epub 2014 Jul 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Bevacizumab	Monoclonal antibody	10 mg/kg	Intravenous
Subject	Cyclophosphamide	Other / unclassified	250 mg/m2	Intravenous
Subject	Fludarabine	Small molecule	25 mg/m2	Intravenous
Subject	Rituximab	Monoclonal antibody	500 mg/m2	Intravenous

FCR and Bevacizumab in the Treatment of Relapsed Chronic Lymphocytic Leukemia (CLL)

Summary

Timeline

Publications

Drugs

Indications